NOK 2.66
(1.92%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 330.83 Million NOK | 201.73% |
2022 | 109.64 Million NOK | -63.04% |
2021 | 296.67 Million NOK | -5.7% |
2020 | 314.61 Million NOK | 0.0% |
2019 | - NOK | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 320.1 Thousand NOK | 0.0% |
2024 Q1 | 320.1 Thousand NOK | -99.9% |
2023 FY | 330.83 Million NOK | 201.73% |
2023 Q4 | 330.83 Million NOK | 0.0% |
2023 Q2 | 59.8 Million NOK | 0.0% |
2023 Q1 | - NOK | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Arctic Bioscience AS | 300.25 Million NOK | -10.186% |
Aqua Bio Technology ASA | 34.42 Million NOK | -860.906% |
ArcticZymes Technologies ASA | 339.32 Million NOK | 2.501% |
BerGenBio ASA | 174.33 Million NOK | -89.77% |
Hofseth BioCare ASA | 390.11 Million NOK | 15.196% |
PCI Biotech Holding ASA | 44.05 Million NOK | -651.044% |
Ultimovacs ASA | 349.03 Million NOK | 5.215% |